Brian Welch
Family · Panama City, FLNPI 1861790537
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 337 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 337 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$975
- Lilly USA, LLC$616
- Pfizer$382
- GSK$335
- Bayer$310
- plus $2K from 23 others
What the payments were for
- Speaking & faculty fees$150%
- Food & beverage$5,354100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 111 | $1,206 |
| AstraZeneca(2 entities) | 50 | $975 |
| Lilly USA, LLC | 42 | $616 |
| Pfizer | 21 | $382 |
| GSK | 21 | $335 |
| Bayer | 13 | $310 |
| Boehringer Ingelheim | 15 | $273 |
| AbbVie | 12 | $212 |
| Exact Sciences | 10 | $161 |
| Astellas Pharma US Inc | 2 | $136 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $125 |
| Merck | 5 | $90 |
| Kowa Pharmaceuticals America, Inc. | 6 | $88 |
| Johnson & Johnson | 5 | $76 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $58 |
| Dexcom, Inc. | 2 | $50 |
| Amgen(2 entities) | 2 | $38 |
| Amarin Pharma, Inc. | 2 | $37 |
| Sanofi Pasteur Inc. | 2 | $30 |
| Avanir Pharmaceuticals, Inc. | 2 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Seqirus USA Inc | 1 | $15 |
| Mckesson Medical-surgical, Inc. | 1 | $15 |
| Novartis | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Medtronic | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$125
- Veozah$118
- FARXIGA$102
- Kerendia$100
How this compares
$5,369 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 84 | $98,003 |
| EliquisApixaban | 98 | $85,123 |
| JardianceEmpagliflozin | 61 | $72,795 |
| OzempicSemaglutide | 39 | $70,125 |
| MounjaroTirzepatide | 41 | $65,178 |
| FarxigaDapagliflozin Propanediol | 47 | $63,140 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 73 | $57,253 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $22,450 |
| MyrbetriqMirabegron | 17 | $22,142 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $20,412 |
| TradjentaLinagliptin | 21 | $17,130 |
| XareltoRivaroxaban | 11 | $16,723 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $15,574 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $9,485 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $6,540 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $273 | $99,41094 claims |
| MerckJanuvia | $90 | $98,00384 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $975 | $90,59189 claims |
| PfizerEliquis, Paxlovid | $382 | $86,552110 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $335 | $77,66594 claims |
| Novo NordiskOzempic | $1,206 | $70,12539 claims |
| Lilly USA, LLCMounjaro | $616 | $65,17841 claims |
| Astellas Pharma US IncMyrbetriq | $136 | $22,14217 claims |
| Johnson & JohnsonXarelto | $76 | $16,72311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.
Other family in Panama City
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
- Ronda CrewsJax Bch$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.